⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of tiakis Biotech AG and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
tiakis Biotech AG
↗Kiel, Germany
tiakis Biotech AG is a clinical-stage biopharmaceutical company based in Kiel, Germany, focused on developing novel tissue-protective therapeutic technologies. The company specializes in anti-inflammatory treatments designed to prevent severe organ damage and failure, particularly following invasive surgeries, and is primarily focused on pulmonary arterial hypertension (PAH).
Their lead candidate, Tiprelestat, is a recombinant human protein (Elafin) that acts as a protease inhibitor. The company is dedicated to shifting treatment paradigms toward preventive approaches for life-threatening conditions, including PAH and postoperative inflammatory complications.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Founded:2000
Ownership:private
Status:operating
FUNDING
Stage:Series A
Investors:Elevat3 Capital
PIPELINE
Stage:Phase 2
Lead Drug Stage:Phase 2
Modalities:Recombinant protein
Active Trials:1
Trial Phases:Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Stanford University (Clinical trial collaboration), Northway Biotech (CDMO partner for manufacturing)
COMPETITION
Position:Emerging
Competitors:Septerna, Philogen, Escient Pharmaceuticals
LEADERSHIP
Key Executives:
Martin Voss - CEO
LINKS
Website:tiakis.bio
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with tiakis Biotech AG. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.